Contineum Therapeutics (CTNM) reported late Monday dosing of the first cohort of patients in the PIPE-791 phase 1b positron emission tomography trial.
The study is expected to measure the correlation of pharmacokinetics to receptor occupancy by positron emission tomography imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis and progressive multiple sclerosis patients, it said.
Contineum said it expects topline data from the trial in Q2 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.